Related to Novartis Teams with Synthetic Genomics Vaccines to Develop Flu Seed Virus Banks

• PPD and Southern Research Ally on Services for Influenza Research
  
• Novartis to Pay $45M Up Front in Cancer Collaboration with Array BioPharma
  
• Vectura Bags $7.5M as Novartis Starts Phase III Development of COPD Therapy
  
• First Replicating Cell Driven by Synthetic Genome Created by Venter Institute
  
• Nonprofit Organizations Join Forces to Evaluate Adjuvants for Pandemic Flu Vaccines
  
• IBM Teams Up with U of Missouri to Establish Cloud Computing Environment
  
• Interim Analysis of Novartis’ Osteoarthritis Therapy Suggests Lack of Efficacy Benefit
  
• GenVec and Novartis Cement Hearing Loss Partnership with Manufacturing Deal
  
• Medicago Wins $21M DARPA Award to Scale Up Production of Flu Vaccines
  
• NIH Bankrolls Six Centers with $100M to Characterize Human Immune Responses
  
• Emergent BioSolutions and TLV Set Up Influenza-Focused JV
  
• Novartis Shells Out $10M for Option to Quark’s Phase II-Stage Synthetic siRNA
  
• NIH to Dole Out More Than $161M Over Five Years to Bolster Pharmacogenomic Research
  
• Ambry Confirmed as First U.S. CSP for NimbleGen Sequence-Capture Solution
  
• Merck & Co. and BGI Intend to Work Together to Advance Genomics in Medicine
  
• NHGRI Fortifies Third-Generation Sequencing Development with $18M
  
• J&J and Crucell in Advanced Negotiations for €1.75B Acquisition Deal
  
• Warner Chilcott Acquires Sole U.S. Rights to Novartis’ Marketed Overactive Bladder Drug for $400M
  
• Alnylam to Nix Jobs in the Wake of Novartis Collaboration Ending
  
• OpGen Closes $17M to Market Microbial Whole-Genome Analysis Platform